Vor Biopharma Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Vor Biopharma Inc. (VOR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 972.42 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-11
- Vor Biopharma Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 551.92K shares, a 86.78% decline year-over-year.
- Vor Biopharma Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 420.50K shares, a 108.00% increase year-over-year.
- Vor Biopharma Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 1.69M shares, a 19.04% decline year-over-year.
- Vor Biopharma Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 773.42K shares.
- Vor Biopharma Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 6.84M shares, a 211.90% increase from fiscal 2024.
- Vor Biopharma Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 2.19M shares, a 6.61% decline from fiscal 2023.
- Vor Biopharma Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 2.35M shares, a 22.91% decline from fiscal 2022.
- Vor Biopharma Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 3.05M shares, a 316.65% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 551.92K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | 972.42K shares 10-Q · filed 2026-08-11 | 2.66M shares derived: sum of 3 quarters · filed 2026-08-11 | 3.43M shares derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | 420.50K shares 10-Q · filed 2026-05-13 | 2.11M shares derived: sum of 2 quarters · filed 2026-05-13 | 2.88M shares derived: sum of 3 quarters · filed 2026-05-13 | 7.06M shares derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-12-31 | 1.69M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | 2.46M shares derived: sum of 2 quarters · filed 2026-03-30 | 6.64M shares derived: sum of 3 quarters · filed 2026-08-11 | 6.84M shares 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | 773.42K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | 4.95M shares derived: sum of 2 quarters · filed 2026-08-11 | 5.15M shares 10-Q · filed 2025-11-13 | 7.23M shares derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-06-30 | 4.18M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | 4.38M shares 10-Q · filed 2026-08-11 | 87.55M shares 10-Q · filed 2025-08-12 | 6.46M shares derived: sum of 3 quarters · filed 2026-08-11 | 4.85M shares derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-03-31 | 202.16K shares 10-Q · filed 2026-05-13 | 4.04M shares 10-Q · filed 2025-05-14 | 2.29M shares derived: sum of 2 quarters · filed 2026-05-13 | 671.79K shares derived: sum of 3 quarters · filed 2026-05-13 | 944.54K shares derived: sum of 4 quarters · filed 2026-05-13 | |||
| 2024-12-31 | 2.08M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | 469.63K shares derived: sum of 2 quarters · filed 2025-11-13 | 742.38K shares derived: sum of 3 quarters · filed 2025-11-13 | 2.19M shares 10-K · filed 2025-03-20 | ||||
| 2024-09-30 | -1.61M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -1.34M shares derived: sum of 2 quarters · filed 2025-11-13 | 108.63K shares 10-Q · filed 2025-11-13 | 2.17M shares 10-Q · filed 2024-11-07 | 208.26K shares derived: sum of 4 quarters · filed 2025-11-13 | |||
| 2024-06-30 | 272.75K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 1.72M shares 10-Q · filed 2025-08-12 | 1.82M shares derived: sum of 3 quarters · filed 2025-08-12 | 1.96M shares derived: sum of 4 quarters · filed 2025-08-12 | ||||
| 2024-03-31 | 1.45M shares 10-Q · filed 2025-05-14 | 1.55M shares derived: sum of 2 quarters · filed 2025-05-14 | 1.69M shares derived: sum of 3 quarters · filed 2025-05-14 | 2.25M shares derived: sum of 4 quarters · filed 2025-05-14 | ||||
| 2023-12-31 | 99.63K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | 239.25K shares derived: sum of 2 quarters · filed 2024-11-07 | 804.25K shares derived: sum of 3 quarters · filed 2024-11-07 | 2.35M shares 10-K · filed 2024-03-20 | ||||
| 2023-09-30 | 139.63K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 704.63K shares derived: sum of 2 quarters · filed 2024-11-07 | 2.25M shares 10-Q · filed 2024-11-07 | 2.68M shares derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | 565.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 2.11M shares 10-Q · filed 2024-08-08 | 2.54M shares derived: sum of 3 quarters · filed 2024-08-08 | 3.21M shares derived: sum of 4 quarters · filed 2024-08-08 | ||||
| 2023-03-31 | 1.54M shares 10-Q · filed 2024-05-09 | 1.97M shares derived: sum of 2 quarters · filed 2024-05-09 | 2.64M shares derived: sum of 3 quarters · filed 2024-05-09 | 2.77M shares derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | 428.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | 1.10M shares derived: sum of 2 quarters · filed 2023-11-07 | 1.23M shares derived: sum of 3 quarters · filed 2023-11-07 | 3.05M shares 10-K · filed 2023-03-23 | ||||
| 2022-09-30 | 669.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 798.97K shares derived: sum of 2 quarters · filed 2023-11-07 | 2.62M shares 10-Q · filed 2023-11-07 | 2.71M shares derived: sum of 4 quarters · filed 2023-11-07 | ||||
| 2022-06-30 | 129.97K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 1.95M shares 10-Q · filed 2023-08-10 | 2.04M shares derived: sum of 3 quarters · filed 2023-08-10 | 2.20M shares derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | 1.82M shares 10-Q · filed 2023-05-11 | 1.91M shares derived: sum of 2 quarters · filed 2023-05-11 | 2.07M shares derived: sum of 3 quarters · filed 2023-05-11 | 2.15M shares derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | 93.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | 252.45K shares derived: sum of 2 quarters · filed 2022-11-10 | 335.95K shares derived: sum of 3 quarters · filed 2022-11-10 | 730.88K shares 10-K · filed 2022-03-14 | ||||
| 2021-09-30 | 159.45K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 242.95K shares derived: sum of 2 quarters · filed 2022-11-10 | 637.88K shares 10-Q · filed 2022-11-10 | |||||
| 2021-06-30 | 83.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 478.43K shares 10-Q · filed 2022-08-11 | ||||||
| 2021-03-31 | 394.93K shares 10-Q · filed 2022-05-12 | |||||||
| 2020-10-31 | 294.12K shares 10-K · filed 2022-03-14 | |||||||
| 2020-09-30 | 2.76M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | 3.46M shares 10-Q · filed 2021-11-10 | ||||||
| 2020-06-30 | 696.51K shares 10-Q · filed 2021-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |